Charlotte Robinson

DocwireNews

An increase in urinary protein concentration is the only clinical urinary biomarker for immunoglobulin A nephropathy (IgAN). Because definitive biomarkers remain elusive, Soo-Young Yoon and others conducted a study with the goal of verifying the predictive value of urinary inflammatory biomarkers at the time of biopsy, as well as the predictive value of noninvasive cytokine biomarkers. Their results were published in BMC Nephrology.The study enrolled 320 patients, of whom 191 were diagnosed with biopsy-proven IgAN; 53 were disease controls with minimal change disease, membranous glomerulonephri&shy;tis, and focal segmental glomerulosclerosis; and 76 were healthy controls. Median patient age was 41.5 &plusmn; 15.9 years, and 47.2% were male.The researchers utilized a multiplex enzyme-linked immunosorbent assay to measure 16 selected urinary inflammatory cytokines, then evaluated the correlation between clinical and pathological features following regression analysis on progression.The IgAN group demonstrated significantly different levels of urinary cytokines versus the disease control and healthy control groups. Urinary levels of the following significantly correlated with both the estimated glomerular filtration rate and urine protein-to-creatinine ratio: B-cell&ndash;activating factor, vascular endothelial growth factor receptor-2, monocyte chemoattractant protein-1, C&ndash;X&ndash;C motif chemokine 10, C&ndash;X&ndash;C motif ligand 16, epidermal growth factor (EGF), endocan, endostatin, growth/differentiation factor-15 (GDF-15), interleukin-6 (IL-6), mannose-binding lectin, transferrin receptor, and kidney injury molecule-1.In addition, a multivariate Cox regression analysis found that urinary EGF (hazard ratio [HR], 0.40; 95% CI, 0.17-0.95; P=.04), GDF-15 (HR, 2.45; 95% CI, 1.01-5.94; P=.048), and IL-6 (HR, 3.02; 95% CI, 1.05-8.64; P=.04) were associated with IgAN progression.The authors acknowledged that the number of participants in the study was small, requiring that results be validated in a large-scale cohort. They suggested that repeated long-term follow-up studies could yield more clinically meaningful outcomes. Considering the long prognosis of IgAN, a 1-year follow-up period may be insufficient for assessing chronic kidney disease progression. The authors acknowledged a few other limitations to the study as well.In sum, urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgAN. &ldquo;The urinary inflammatory biomarkers in the IgAN group were dysregulated compared with those in the disease control and healthy control groups. Specific urinary cytokines, such as GDF-15, IL-6, and EGF, significantly strengthened the predictability of IgAN prognosis. These candidates, as early prognostic biomarker candidates, may assist in the formulation of therapeutic strategies for patients with IgAN,&rdquo; the researchers concluded.Source: <a href="https://doi.org/10.1186/s12882-024-03574-2" target="_blank" rel="noopener">BMC Nephrology</a>

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Latest News

Predictive Value of Urinary Inflammatory Biomarkers for IgAN

IgA Nephropathy

Urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgA nephropathy (IgAN).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe